MLP SE (MLP):企業の財務・戦略的SWOT分析

◆英語タイトル:MLP SE (MLP) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA8011606
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月12日
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:金融サービス
◆販売価格オプション(消費税別)
Single UserUSD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

MLP SE (MLP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MLP SE (MLP), formerly MLP AG, is an independent financial consulting company. It provides customized financial solutions to individuals, corporate, and institutional customers. The company provides consulting for academics and other discerning clients, majorly related to insurance, occupational pension provision schemes, investments, loans and mortgages, and brokering of contracts. It offers wealth and investment management solutions to institutional investors and high net-worth individuals. The company provides underwriting services for private and commercial non-life insurance products, and conducts brokerage activities. It offers occupational pension provision management for companies. MLP is headquartered in Wiesloch, Germany.MLP achieved more in 2016 than could have been expected at the start of the year. We increased revenue in the field of old-age provision and expanded market shares in key consulting areas, accelerated the process for winning new clients and laid the foundations for further cost reductions. We can therefore rate the financial year as satisfactory in the light of market conditions.

However, we do not want to content ourselves with that for the future. One of the reasons why MLP enjoys such an excellent position in the competitive environment is because we were quick to start work on restructuring the company with a clear direction in the last few years, while at the same time keeping a tight rein on costs.

If we compare the commission income from 2005 – i.e. the year before the expansion of our wealth management operations – with 2016, three facts become clear:

Our revenue mix is today significantly more balanced and we have compensated for market-related declines in the old-age provision segment of around € 150 million.

The proportion of recurring revenue has increased significantly – from around 30 to more than 60 percent today. The company is therefore now on a much sounder financial footing.

Setting old-age provision aside, sales revenues increased by an average of around 13 percent per year during this period.

A look at the development of total revenue over the last five years also shows how we have made gradual yet continuous progress. In fact we are now above the level recorded in 2012, a particularly strong year. In comparison with 2015, total revenue has increased by 10 percent to € 610.4 million.

MLP recorded good gains in 2016, particularly in the non-life insurance area, where revenue increased by 93 percent to € 105.6 million. Around € 68.7 million of this can be attributed to the ongoing positive development of DOMCURA, which we acquired as a subsidiary mid-2015. Developments in the old-age provision area were also pleasing, with revenues increasing by 3 percent to € 221.5 million. This successful development can largely be attributed to a strong final quarter. This means that MLP recorded gains in the old-age provision segment for three quarters in succession in 2016.

At € 166.4 million, revenue in wealth management is slightly above the previous year’s record figure, despite selling the former FERI EuroRating Services in mid-2016. With revenue of € 15.4 million, the loans and mortgages area is slightly below the record level recorded in 2015. At € 15.4 million, other commission and fees, which are mainly attributable to the brokerage of real estate objects, remain at the previous year’s level. At € 45.8 million, revenue in the health insurance area also remained at the previous year’s level.

These developments should also be seen as positive in the light of market conditions that remain extremely difficult. In the private health insurance area, the number of persons holding comprehensive health insurance fell for the fifth year in succession, while the wealth management is facing negative market developments due to the massive monetary distortions. However, the old-age provision area continues to display the greatest market turbulence. Indeed, new business throughout the sector only increased 1.5 percent over the previous year’s low level.

At MLP, the premium sum of new business in the old-age provision area increased by 6.2 percent. MLP’s ability to adapt quickly to the new product portfolio is one key reason for this excellent development. We also recorded better development than the industry in the private health insurance area with a slight increase in the number of persons holding comprehensive health insurance.

This all resulted in operating earnings before interest and taxes (operating EBIT) – i.e. before one-off exceptional costs – increasing by 14.3 percent to € 35.1 million. As announced, one-off exceptional cost were accrued within the scope of the efficiency programme. These expenses were € 15.4 million, resulting in an EBIT of € 19.7 million. One-off exceptional costs also had an impact on net profit for the period, which was € 14.7 million.

Taking earnings trends and current capital requirements into account and subject to approval by the Supervisory Board, the Executive Board proposes a dividend of 8 cents per share. At 60 percent, the distribution rate is set to increase slightly over the previous year and lies within the announced corridor.

In 2017, we added two new topics to our strategic agenda. The first focuses on extending our corporate and economic scope for action through an optimisation of corporate structure, while the second revolves around strengthening our university segment in the private client business.

The objective of the corporate structure optimisation is to significantly extend MLP’s scope for action, which had become increasingly restricted in the last few years. This is due to the significantly stricter capital requirements for banks that have been in place since the outbreak of the financial crisis – such as Basel III and others. We are not complaining about this and are still of the opinion that events such as those that occurred during the financial crisis need to be prevented through adequate measures. For MLP, however, the regulatory pendulum is now swinging too far in the other direction. Our banking business is low-risk. ??et despite this, the aforementioned new requirements placed on classic banks are impacting our operations across the board, meaning that the proportionality of revenue and costs has shifted significantly in the current Group structure.

With the step we are preparing in the current year and intend to introduce early in 2018, we will bundle all regulated bank activities at one company, while all other consulting services will then be provided by the other company. This offers the advantage that we will be able to gradually increase our free own funds by around € 75 million up to 2021 – assuming the current capital adequacy requirements remain unchanged. ??e will use this significantly improved position in our own funds primarily for investments in the future and for acquisitions. In addition it will also provide us with greater freedom for dividend pay-outs. We can envisage continuing to make acquisitions in three main segments – at FERI, at DOMCURA, as well as in MLP’s traditional private client business.

Regarding the strengthening of the university segment: MLP has deep roots in the private client business. This also includes a highly visible presence in the university segment, in which MLP consultants continue to win a large proportion of our new clients – both online and offline. In the last few years, we have already introduced comprehensive measures to boost our presence in this segment with increasing numbers of academics. For example, introduction of our further training allowance has made it easier for young consultants in particular to make the transition into self-employment. The package is being well received and has made a key contribution to stabilising consultant numbers.

We are now taking the next step with the introduction of a dedicated divisional board member for the young segment. By focusing on core topics for young clients and consultants, we pave the way for faster acquisition of new clients and consultants – and thereby further strengthen our presence.

In addition, we are persevering with our strategic approach of recent years.

The ongoing diversification of our revenue structure aims at further reducing the impact of short-term market influences on MLP. Therefore the non-life insurance and wealth management consulting areas will be in the focus also for 2017.

??e are also pressing ahead with digitalisation. In 2016, we collaborated with a fintech to introduce online sales for electronics and travel health insurance policies – i.e. for basic products that do not require intensive consulting services – and are already seeing initial successes. In addition to this, we have won more than 50,000 initial contacts online and on social media platforms. As these examples show, the key here is to remove any notion of online OR offline and instead focus on bringing the two concepts together. In 2017, we will release more products for online sales and launch the first phase of our new client portal. This will provide clients with all financial information at a glance, accompanied by a personal budget book. ??e are convinced that digitalisation – understood correctly – can actually help further underline the importance of face-to-face consulting.

In terms of cost management, we will harvest the fruit of our efforts in 2017. In the past year, MLP laid the foundations for permanently reducing the cost base of administrative expenses by around € 15 million relative to 2015 from 2017 onwards. In 2017, this low cost base will be subjected to additional one-off exceptional costs of around € 9 million for implementing the new Group structure. Due to the planned increase in own funds, we can cushion the effect of these one-off expenses for our shareholders. Maintaining a distribution rate of 50 to 70 percent, we will base our dividend proposal for the financial year 2017 on operating net profit, i.e. before one-off exceptional costs.

Overall, we expect to record EBIT for the current year of at least € 36 million. Accordingly, we anticipate an operating EBIT of at least € 45 million.

We would be delighted if you – our shareholders – continued to accompany us along this path. On behalf of the entire Executive Board, I would like to express my sincere thanks for the trust you showed in us throughout the last financial year.

Equally sincere thanks are also due to all client consultants and employees in the Group.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
MLP SE – Key Facts 5
MLP SE – Key Employees 6
MLP SE – Key Employee Biographies 7
MLP SE – Major Products and Services 8
MLP SE – History 9
MLP SE – Company Statement 11
MLP SE – Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Company Overview 14
MLP SE – Business Description 16
MLP SE – SWOT Analysis 17
SWOT Analysis – Overview 17
MLP SE – Strengths 17
MLP SE – Weaknesses 18
MLP SE – Opportunities 19
MLP SE – Threats 20
MLP SE – Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios – Capital Market Ratios 22
Financial Ratios – Annual Ratios 23
Performance Chart 26
Financial Performance 26
Financial Ratios – Interim Ratios 27
Financial Ratios – Ratio Charts 28
Section 4 – Appendix 29
Methodology 29
Ratio Definitions 29
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
MLP SE, Key Facts 5
MLP SE, Key Employees 6
MLP SE, Key Employee Biographies 7
MLP SE, Major Products and Services 8
MLP SE, History 9
MLP SE, Subsidiaries 13
MLP SE, Key Competitors 21
MLP SE, Ratios based on current share price 22
MLP SE, Annual Ratios 23
MLP SE, Annual Ratios (Cont...1) 24
MLP SE, Annual Ratios (Cont...2) 25
MLP SE, Interim Ratios 27
Currency Codes 29
Capital Market Ratios 29
Equity Ratios 30
Profitability Ratios 30
Cost Ratios 31
Liquidity Ratios 31
Leverage Ratios 32
Efficiency Ratios 32

★海外企業調査レポート[MLP SE (MLP):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HCA Healthcare Inc (HCA)-製薬・医療分野:企業M&A・提携分析
    Summary HCA Healthcare Inc (HCA), formerly known as HCA Holdings Inc, is a health care services company that provides a wide range of services in specialties including internal medicine; general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics. It also offers outpatient and an …
  • Genentech Inc:医療機器:M&Aディール及び事業提携情報
    Summary Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including bio-oncology, immunology, ophthalmology …
  • AVBOB Mutual Assurance Society:企業の戦略・SWOT・財務分析
    AVBOB Mutual Assurance Society - Strategy, SWOT and Corporate Finance Report Summary AVBOB Mutual Assurance Society - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Eindec Corporation Ltd (42Z):企業の財務・戦略的SWOT分析
    Eindec Corporation Ltd (42Z) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Carisma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Carisma Therapeutics Inc (Carisma Therapeutics), formerly CARMA Therapeutics LLC, is a biotechnology company with focus on the discovery and development of macrophage-based immunotherapeutics for the treatment of cancer. The company exploits its proprietary CAR-macrophage platform to provide …
  • AGA Rangemaster Group Ltd:企業の戦略的SWOT分析
    AGA Rangemaster Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • JCR Pharmaceuticals Co Ltd (4552):製薬・医療:M&Aディール及び事業提携情報
    Summary JCR Pharmaceuticals Co Ltd (JCR) manufactures, sells, buys, imports and exports pharmaceutical products. It provides biopharmaceuticals in the field of regenerative medicine for the treatment of rare diseases. The company offers pharmaceuticals to treat growth hormone deficiency, turner synd …
  • Centre for Drug Research and Development-製薬・医療分野:企業M&A・提携分析
    Summary Centre for Drug Research and Development (CDRD) is a drug development and commercialization center that provides infrastructure to transform basic health research in academic institutions and early-stage therapeutic technologies into new medicines. The center offers target validation, screen …
  • Commonwealth Bank of Australia:企業の戦略・SWOT・財務情報
    Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report Summary Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Snowy Hydro Ltd-エネルギー分野:企業M&A・提携分析
    Summary Snowy Hydro Limited (Snowy Hydro) is an integrated energy utility that generates, supplies, trades, and retails electricity. The company produces power from gas and hydro sources. It owns and operates gas plants: Valley Power, Laverton North, and Colongra; and Snowy Mountains Scheme hydroele …
  • Sanderson Group plc (SND):企業の財務・戦略的SWOT分析
    Summary Sanderson Group plc (Sanderson) is a technology company that provides software solutions. The company’s products include Elucid, Swords, Unity, UnityF8 and Payroll Bureau. Sanderson offers services such as helpdesk and IT support, managed services, IT consultancy, project management, impleme …
  • Flotek Industries Inc (FTK):石油・ガス:M&Aディール及び事業提携情報
    Summary Flotek Industries Inc (Flotek) is a diversified company that develops and delivers chemistry based technology solutions for energy, industrial and consumer applications. The company offers stimulation chemistry, cementing chemistry, improved oil recovery chemistry, drilling fluid additives, …
  • Dottikon ES Holding AG (DESN):製薬・医療:M&Aディール及び事業提携情報
    Summary Dottikon ES Holding AG (Dottikon) manufactures and commercializes active pharmaceutical ingredients (APIs), performance chemicals and intermediates for chemical and pharmaceutical industries. The company finds novel uses for hazardous reactions and continuous processing that facilitate the r …
  • Stereotaxis Inc (STXS)-製薬・医療分野:企業M&A・提携分析
    Summary Stereotaxis Inc (Stereotaxis) is a healthcare technology company that designs, manufactures and markets robotic systems and instruments for electrophysiologists for the treatment of cardiac arrhythmias. Its flagship product, Epoch Solution is an advanced remote robotic navigation system for …
  • Clarius Group Limited (CND):企業の財務・戦略的SWOT分析
    Clarius Group Limited (CND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Alimentation Couche-Tard Inc. (ATD.B)-石油・ガス分野:企業M&A・提携分析
    Summary Alimentation Couche-Tard Inc. (Couche-Tard) is a retail company that operates an extensive network of convenience stores. The company principally offers food and non-food items as well as transportation fuels. Couche-Tard products include tobacco, alcohol, grocery items, candy, snacks and va …
  • Faron Pharmaceuticals Oy (FARN)-製薬・医療分野:企業M&A・提携分析
    Summary Faron Pharmaceuticals Oy (Faron Pharma) is a drug company that carries out clinical stage drug discovery and development. The company's product portfolio includes traumakine; clevegen; farbetic, an AOC3 inhibitor and D-ARDS, a diagnostic tool. Its traumakine clinical programme manages the tr …
  • Minnesota Municipal Power Agency:企業の戦略的SWOT分析
    Minnesota Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Scatec Solar ASA (SSO):企業の財務・戦略的SWOT分析
    Scatec Solar ASA (SSO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析
    Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆